Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors Softcover Repri Edition Contributor(s): Bonadonna, Gianni (Editor), Mathe, G. (Editor), Salmon, S. E. (Editor) |
|
ISBN: 3642813348 ISBN-13: 9783642813344 Publisher: Springer OUR PRICE: $104.49 Product Type: Paperback - Other Formats Published: February 2012 |
Additional Information |
BISAC Categories: - Medical | Oncology - General |
Dewey: 616.994 |
Series: Recent Results in Cancer Research |
Physical Information: 0.97" H x 6.69" W x 9.61" (1.68 lbs) 468 pages |
Descriptions, Reviews, Etc. |
Publisher Description: A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described. The results at 2 years are recorded together with details of toxicity. Future plans are discussed briefly. Acknowledgement We wish to acknowledge the participation of all the collaborators in this study, the co-ordinator Dr. ERICA MANSBACHER and the support of Action Cancer in Belfast. References 1. Ahmann, D. L., O'Connell, M. J., Hahn, R. G., Bisel, H. F., Lee, R. A., Edmonson, J. H.: An evaluation of early or delayed adjuvant chemotherapy in premenopause1 patients with advanced breast cancer undergoing oophorectomy. New Engl. J. Med. 297, 356-360 (1977) 2. Ahmann, D. L., Scanlon, P. W., Bisel, H. F., Edmonson, J. H., Frytak, S., Payne, W. S., O'Fallon, J. R., Hahn, R. J., Ingle, J. N., O'Connell, M. J., Rubin, J.: Repeated adjuvant chemotherapy with Phenyl-alanine mustard, or 5-Fluorouracil, Cyclophosphamide and Prednisone with or without radiation after mastectomy for breast cancer. Lancet 1978//, 893-896 3. Bonadonna, G., Rossi, A., Valagussa, P., Banfi, A., Veronesi, U.: The CMF program for operable breast cancer with positive axillary nodes. Cancer 39, 2904-2915 (1977) 4. Edelstyn, G. A., Bates, T. S., Brinkley, D., Macrae, K. D., Spittle, M., Wheeler, T.: Comparison of 5-day, I-day and 2-day cyclical combination chemotherapy in advanced breast cancer. |